Abstract:
Background and aims: The COVID-19 pandemic and its consequences represent a major challenge to
the mental health and well-being of the general population. Building on previous work on the potential
long-term benefits of psychedelics, we hypothesized that lifetime use of these drugs could be linked to
better mental health indicators in the context of the ongoing pandemic. Methods: Two anonymous
online surveys were conducted between April and June 2020, including questions about lifetime
experience with psychedelics and other psychoactive drugs, and psychometric scales designed to
measure personality traits, anxiety, negative, and positive affect, well-being, and resilience. Principal
component analysis was applied to divide the sample into groups of subjects based on their drug use
reports. Results: Five thousand six hundred eighteen participants (29.15 ± 0.12 years, 71.97% female)
completed both surveys and met the inclusion criteria, with 32.43% of the sample reporting at least one
use of a psychedelic drug. Preliminary analyses showed that certain psychedelics were linked to
improved mental health indicators, while other psychoactive drugs exhibited the opposite behavior.
Lifetime psychedelic use was linked to increased openness and decreased conscientiousness, and to
higher scores of positive affect. The reported number of past psychedelic experiences predicted higher
scores of the secondary personality trait beta factor, which has been interpreted as a measure of
plasticity. No significant associations between lifetime use of psychedelics and indicators of impaired
mental health were observed. Conclusion: We did not find evidence of an association between lifetime
use of psychedelics and poor mental health indicators. Conversely, experience with psychedelic drugs
was linked to increased positive affect and to personality traits that favor resilience and stability in the
light of the ongoing crisis.